MorphoSys (ETR:MOR) received a €91.20 ($112.59) price objective from research analysts at Bryan, Garnier & Co in a report released on Wednesday. The brokerage presently has a “buy” rating on the stock. Bryan, Garnier & Co’s price target suggests a potential upside of 6.23% from the stock’s current price.
A number of other research analysts also recently commented on the company. JPMorgan Chase & Co. set a €97.00 ($119.75) price objective on MorphoSys and gave the company a “buy” rating in a report on Friday, December 29th. Oddo Bhf set a €90.00 ($111.11) price objective on MorphoSys and gave the company a “buy” rating in a report on Tuesday, February 20th. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the stock a “buy” rating in a research note on Thursday, December 7th. HSBC set a €64.00 ($79.01) price target on MorphoSys and gave the stock a “sell” rating in a research note on Friday, January 19th. Finally, Independent Research set a €93.00 ($114.81) price target on MorphoSys and gave the stock a “buy” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. MorphoSys has an average rating of “Hold” and a consensus target price of €83.75 ($103.39).
MorphoSys (ETR MOR) opened at €85.85 ($105.99) on Wednesday. MorphoSys has a 1-year low of €49.63 ($61.27) and a 1-year high of €87.40 ($107.90). The company has a market capitalization of $2,550.00 and a PE ratio of -29.10.
COPYRIGHT VIOLATION NOTICE: “Bryan, Garnier & Co Analysts Give MorphoSys (MOR) a €91.20 Price Target” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/03/14/bryan-garnier-91-20-price-target.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.